Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤ENSURE-1 and ENSURE-2 top-line data expected in December 2026
- ➤Cash and equivalents $132.0 million; runway expected into late 2027
- ➤Third-quarter net loss $42.3 million, or $0.99 per share
- ➤PROTECT-MS Phase 3 initiation ongoing; first patient expected in the first half of 2027
- ➤R&D expenses $23.9 million, up from $20.0 million year over year
Expert Statements
Erik Lundgren, Chief Executive Officer of Immunic
“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history”
Erik Lundgren, Chief Executive Officer of Immunic
“We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS.”
Erik Lundgren, Chief Executive Officer of Immunic
“We believe vidofludimus calcium has the potential to address mechanisms associated with both the neurodegenerative and inflammatory drivers of the disease, which, if confirmed in our Phase 3 trials, could offer a differentiated treatment option in MS.”
Erik Lundgren, Chief Executive Officer of Immunic
“Subject to positive ENSURE results, we are preparing for a potential New Drug Application (NDA) submission in relapsing MS, while we continue to advance our Phase 3 program in progressive MS.”
Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
“We were fortunate to present exciting data in four posters at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, which added complementary clinical and mechanistic evidence supporting the potential of vidofludimus calcium to address existing unmet needs in MS”
Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
“Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026.”
Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
“Our teams remain focused on this readout and readiness for a potential NDA submission should the results be positive.”
Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
“In parallel, the Phase 2 CALLIPER data along with the insights shared by leading MS experts at our two recent R&D Days support the rational for our Phase 3 PROTECT-MS trial in progressive MS, with initiation ongoing and first-patient-enrolled expected in the first half of 2027.”
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update PR Newswire
– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 –
Get started
Create a free account to read the full story.